Swedish biopharma company BioArctic AB has announced that it will utilize the proprietary epitope mapping technology, Seqitope™, from AAX Biotech.
AAX Biotech is a biotech company that specializes in innovative technologies for improving antibody-based medicines. The company’s two pioneering technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market. This marks a significant milestone for AAX Biotech, highlighting the company’s role in advancing research with its Seqitope™ technology—a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
“Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases which affect millions of persons worldwide,” says Maria L. Knudsen, CEO of AAX Biotech. “We are fully committed to this challenging project and are eager to apply our technology to support BioArctic.”
For more information about this partnership between BioArctic AB and AAX Biotech AB, please contact Maria Lisa Knudsen at [maria.knudsen@aaxbiotech.com](mailto:maria.knudsen@aaxbiotech.com) or visit [www.aaxbiotech.com](http://www.aaxbiotech.com).
